Aviso Financial Inc. Increases Stake in Becton, Dickinson and Company $BDX

Key Points

• Aviso Financial Inc. has increased its holdings in Becton, Dickinson and Company by 7.7%, owning 21,558 shares worth approximately $4.94 million.
• Becton, Dickinson and Company reported earnings per share of $3.68 for the last quarter, surpassing analysts' expectations and showing a 10.4% increase in revenue compared to the previous year.
• The company's stock is currently trading at around $195.88, with institutional investors holding over 86.97% of the company's shares.

Aviso Financial Inc. grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 7.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,558 shares of the medical instruments supplier's stock after purchasing an additional 1,538 shares during the period. Aviso Financial Inc.'s holdings in Becton, Dickinson and Company were worth $4,938,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Brighton Jones LLC boosted its stake in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after purchasing an additional 877 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Becton, Dickinson and Company by 50.6% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier's stock valued at $18,808,000 after purchasing an additional 27,581 shares in the last quarter. Foster Victor Wealth Advisors LLC bought a new stake in shares of Becton, Dickinson and Company during the 1st quarter valued at about $6,406,000. GAMMA Investing LLC boosted its stake in shares of Becton, Dickinson and Company by 29.9% during the 1st quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier's stock valued at $744,000 after purchasing an additional 748 shares in the last quarter. Finally, Ritholtz Wealth Management bought a new stake in shares of Becton, Dickinson and Company during the 1st quarter valued at about $224,000. Institutional investors own 86.97% of the company's stock.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the transaction, the executive vice president owned 4,887 shares in the company, valued at $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Claire Fraser sold 863 shares of the company's stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $192.30, for a total transaction of $165,954.90. Following the sale, the director directly owned 23,143 shares of the company's stock, valued at approximately $4,450,398.90. This represents a 3.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 3,214 shares of company stock worth $579,206 over the last quarter. Company insiders own 0.36% of the company's stock.

Wall Street Analysts Forecast Growth

BDX has been the topic of a number of research reports. Wall Street Zen raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. William Blair lowered shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Thursday, May 1st. Citigroup lowered shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and dropped their price objective for the stock from $217.00 to $185.00 in a research note on Thursday, May 22nd. Raymond James Financial lowered shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Friday, May 2nd. Finally, Morgan Stanley boosted their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Four research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $211.44.

Becton, Dickinson and Company Stock Down 1.4%

Shares of NYSE BDX traded down $2.7620 during midday trading on Thursday, hitting $196.4380. The stock had a trading volume of 1,304,192 shares, compared to its average volume of 2,656,939. The business's 50 day moving average is $179.66 and its 200-day moving average is $196.25. The company has a market cap of $56.30 billion, a P/E ratio of 35.33, a PEG ratio of 1.48 and a beta of 0.20. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. The company had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm's revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be given a dividend of $1.04 per share. The ex-dividend date is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a yield of 2.1%. Becton, Dickinson and Company's dividend payout ratio is 74.82%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.